Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor

T A Waldmann, W C Greene, P S Sarin, C Saxinger, D W Blayney, W A Blattner, C K Goldman, K Bongiovanni, S Sharrow, J M Depper, T A Waldmann, W C Greene, P S Sarin, C Saxinger, D W Blayney, W A Blattner, C K Goldman, K Bongiovanni, S Sharrow, J M Depper

Abstract

Adult T cell leukemia (ATL) and Sézary leukemia are malignant proliferations of T lymphocytes that share similar cell morphology and clinical features. ATL is associated with HTLV (human T cell leukemia/lymphoma virus), a unique human type C retrovirus, whereas most patients with the Sézary syndrome do not have antibodies to this virus. Leukemic cells of both groups were of the T3, T4-positive, T8-negative phenotype. Despite the similar phenotype, HTLV-negative Sézary leukemic cells frequently functioned as helper cells, whereas some HTLV-positive ATL and HTLV-positive Sézary cells appeared to function as suppressors of immunoglobulin synthesis. One can distinguish the HTLV-positive from the HTLV-negative leukemias using a monoclonal antibody (anti-Tac) that appears to identify the human receptor for T cell growth factor (TCGF). Resting normal T cells and most HTLV-negative Sézary cells were Tac-negative, whereas all ATL cell populations were Tac-positive. The observation that ATL cells manifest TCGF receptors suggests the possibility that an abnormality of the TCGF-TCGF receptor system may partially explain the uncontrolled growth of these cells.

References

    1. Science. 1976 Sep 10;193(4257):1007-8
    1. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5680-3
    1. Nature. 1982 Nov 18;300(5889):267-9
    1. Virology. 1982 Oct 30;122(2):297-305
    1. J Exp Med. 1982 Oct 1;156(4):1065-76
    1. Science. 1983 Feb 18;219(4586):856-9
    1. J Infect Dis. 1983 Mar;147(3):406-16
    1. JAMA. 1983 Aug 26;250(8):1048-52
    1. Nature. 1983 Oct 20-26;305(5936):733-6
    1. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6957-61
    1. Acta Pathol Jpn. 1982;32 Suppl 1:171-85
    1. J Immunol. 1976 Nov;117(5 Pt 1):1538-44
    1. Blood. 1977 Sep;50(3):481-92
    1. N Engl J Med. 1978 Jan 12;298(2):66-72
    1. Clin Immunol Immunopathol. 1978 May;10(1):24-34
    1. N Engl J Med. 1978 Dec 7;299(23):1281-4
    1. Nature. 1979 Feb 8;277(5696):478-80
    1. Blood. 1979 Apr;53(4):642-51
    1. Clin Immunol Immunopathol. 1979 Mar;12(3):341-50
    1. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4061-5
    1. J Immunol. 1980 Mar;124(3):1301-7
    1. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1588-92
    1. Immunol Rev. 1979;47:3-61
    1. Clin Immunol Immunopathol. 1980 Sep;17(1):43-54
    1. J Immunol. 1981 Apr;126(4):1393-7
    1. J Immunol. 1981 Apr;126(4):1398-403
    1. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
    1. Cell. 1981 Mar;23(3):771-80
    1. J Exp Med. 1981 Jul 1;154(1):156-67
    1. J Exp Med. 1981 Aug 1;154(2):459-67
    1. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4515-9
    1. Nature. 1981 Nov 19;294(5838):268-71
    1. Nature. 1981 Nov 19;294(5838):271-3
    1. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80
    1. J Immunol. 1982 Aug;129(2):592-5
    1. Proc Natl Acad Sci U S A. 1982 Apr;79(7):2365-9
    1. Blood. 1982 Sep;60(3):545-57
    1. Adv Immunol. 1982;32:1-63
    1. Science. 1982 Oct 29;218(4571):471-3
    1. Int J Cancer. 1982 Sep 15;30(3):257-64
    1. J Clin Invest. 1976 Dec;58(6):1297-306

Source: PubMed

3
Prenumerera